News on qPCR, digital PCR, amplification, point-of-care testing platforms in genetics, genomics, and molecular diagnostics.
The revenue growth was driven in part by sales generated by Australian reagent maker TGR Biosciences, which Expedeon acquired in May last year.
Among the claims, NeuMoDx has alleged that BD was kept up to date on the firm's technology as it was developed and that one of the patents was duplicitously expanded by BD.
The firm said its platform provides sample-to-answer results for two of the most frequently tested sexually transmitted infections, enabling rapid testing and treatment.
The company said it is pushing to begin simultaneous clinical trials for multiple small panel-based tests for its sample-to-answer Savanna platform.
The firm experienced a 30 percent jump in sales of immunoassays, attributed in part to a $6.2 million increase in influenza revenues year-over-year.
